Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC28-E vs Eylea in Diabetic Macular Edema
CTR20231225Phase 3Completed
- Sponsor
- Rongchang Pharmaceuticals
- Start
- May 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of eflimrufusp alfa in diabetic macular edema (DME), sponsored by Rongchang Pharmaceuticals. Started May 2023; status: completed.
02
Drugs
eflimrufusp alfa
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on CTR20231225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231225.